X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with Fresenius Kabi Onco. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs FRESENIUS KABI ONCO. - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA FRESENIUS KABI ONCO. AUROBINDO PHARMA/
FRESENIUS KABI ONCO.
 
P/E (TTM) x 14.6 22.1 66.1% View Chart
P/BV x 3.8 3.1 121.3% View Chart
Dividend Yield % 0.4 0.0 -  

Financials

 AUROBINDO PHARMA   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-17
FRESENIUS KABI ONCO.
Mar-13
AUROBINDO PHARMA/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs895176 508.5%   
Low Rs62279 792.4%   
Sales per share (Unadj.) Rs254.637.7 675.6%  
Earnings per share (Unadj.) Rs39.35.1 771.2%  
Cash flow per share (Unadj.) Rs46.66.7 692.8%  
Dividends per share (Unadj.) Rs2.500-  
Dividend yield (eoy) %0.30-  
Book value per share (Unadj.) Rs160.042.5 376.0%  
Shares outstanding (eoy) m585.88158.23 370.3%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.03.4 88.2%   
Avg P/E ratio x19.325.0 77.3%  
P/CF ratio (eoy) x16.318.9 86.0%  
Price / Book Value ratio x4.73.0 158.5%  
Dividend payout %6.40-   
Avg Mkt Cap Rs m444,39020,135 2,207.1%   
No. of employees `00014.01.2 1,213.7%   
Total wages/salary Rs m17,678703 2,513.9%   
Avg. sales/employee Rs Th10,667.85,176.2 206.1%   
Avg. wages/employee Rs Th1,264.3610.4 207.1%   
Avg. net profit/employee Rs Th1,645.8699.6 235.3%   
INCOME DATA
Net Sales Rs m149,1575,963 2,501.4%  
Other income Rs m1,15918 6,438.3%   
Total revenues Rs m150,3165,981 2,513.2%   
Gross profit Rs m34,3431,430 2,401.4%  
Depreciation Rs m4,276258 1,658.1%   
Interest Rs m667-26 -2,566.2%   
Profit before tax Rs m30,5581,216 2,512.6%   
Minority Interest Rs m500-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-68 0.0%   
Tax Rs m7,597342 2,219.9%   
Profit after tax Rs m23,012806 2,855.4%  
Gross profit margin %23.024.0 96.0%  
Effective tax rate %24.928.1 88.4%   
Net profit margin %15.413.5 114.2%  
BALANCE SHEET DATA
Current assets Rs m92,0625,102 1,804.6%   
Current liabilities Rs m66,2232,385 2,776.2%   
Net working cap to sales %17.345.6 38.0%  
Current ratio x1.42.1 65.0%  
Inventory Days Days106150 70.6%  
Debtors Days Days68113 59.7%  
Net fixed assets Rs m62,9195,148 1,222.2%   
Share capital Rs m586158 370.4%   
"Free" reserves Rs m93,1336,556 1,420.7%   
Net worth Rs m93,7196,732 1,392.2%   
Long term debt Rs m1,814952 190.5%   
Total assets Rs m162,49410,388 1,564.2%  
Interest coverage x46.8-45.8 -102.2%   
Debt to equity ratio x00.1 13.7%  
Sales to assets ratio x0.90.6 159.9%   
Return on assets %14.67.5 194.1%  
Return on equity %24.612.0 205.1%  
Return on capital %32.714.6 224.2%  
Exports to sales %074.5 0.0%   
Imports to sales %024.8 0.0%   
Exports (fob) Rs mNA4,441 0.0%   
Imports (cif) Rs mNA1,477 0.0%   
Fx inflow Rs m75,8385,298 1,431.5%   
Fx outflow Rs m30,2241,772 1,705.5%   
Net fx Rs m45,6133,525 1,293.9%   
CASH FLOW
From Operations Rs m32,7861,274 2,573.3%  
From Investments Rs m-17,870-1,204 1,484.0%  
From Financial Activity Rs m-19,153-196 9,766.8%  
Net Cashflow Rs m-4,239-126 3,356.1%  

Share Holding

Indian Promoters % 54.1 0.0 -  
Foreign collaborators % 0.0 81.0 -  
Indian inst/Mut Fund % 8.0 0.3 2,650.0%  
FIIs % 27.7 9.6 288.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 9.1 112.1%  
Shareholders   69,601 42,599 163.4%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   ABBOTT INDIA  JUBILANT LIFE SCIENCES  DIVIS LABORATORIES  PFIZER  ALKEM LABORATORIES  

Compare AUROBINDO PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 219 Points Lower; Energy and Auto Stocks Witness Selling(Closing)

After witnessing volatile trades during the day, Indian share markets ended their session on a negative note. Losses were largely seen in the oil & gas sector, auto sector.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 0.4%

May 30, 2018 | Updated on May 30, 2018

For the quarter ended March 2018, AUROBINDO PHARMA has posted a net profit of Rs 5 bn (down 0.4% YoY). Sales on the other hand came in at Rs 40 bn (up 11.2% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

This Behaviour is Injurious to Wealth Building(Sector Info)

Jun 13, 2018

Blindly following the herd can be the biggest wealth destroyer.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Jun 25, 2018 03:35 PM

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA - WOCKHARDT LTD. COMPARISON

COMPARE AUROBINDO PHARMA WITH

MARKET STATS